Medikinet Cr (Methylphenidate Hydrochloride)

Methylphenidate works by blocking the reuptake of dopamine and norepinephrine in the brain, which raises the levels of these neurotransmitters at synaptic sites. The enhanced catecholamine activity improves neural signaling in pathways that control attention, impulse control, and wakefulness.

The appropriate dose of Medikinet CR is individualized and determined by the prescribing healthcare professional based on the patient’s age, clinical response, and tolerability. Dosage adjustments are made under medical supervision to achieve optimal therapeutic effect while minimizing side effects.

Safety data for methylphenidate use in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Medikinet CR, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details and any necessary import documentation.

Medikinet CR is a long‑acting formulation of methylphenidate, offering once‑daily dosing and smoother plasma concentration curves compared with immediate‑release methylphenidate. Compared with amphetamine‑based stimulants, methylphenidate generally has a lower risk of certain cardiovascular effects, but individual response varies, so clinicians choose based on efficacy, tolerability and patient preference.

Medikinet CR tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the packaging.

Medikinet CR is taken orally, usually once daily in the morning. The tablet should be swallowed whole with a full glass of water and not be chewed, crushed, or split, to maintain the modified‑release profile and ensure consistent drug delivery.

Serious risks include cardiovascular events such as hypertension, chest pain, or arrhythmias, as well as psychiatric effects like new or worsening psychosis, mania, or severe anxiety. Rarely, allergic reactions such as rash, swelling, or anaphylaxis may occur. Patients should be monitored closely for these events.

Medikinet CR is contraindicated in individuals with known hypersensitivity to methylphenidate or any tablet excipients, those with severe cardiovascular disorders (e.g., recent myocardial infarction, uncontrolled hypertension), and patients currently taking monoamine oxidase inhibitors (MAOIs) or who have used them within the past 14 days.